Johnson & Johnson Dives into Gene Therapy and AI-Driven Repurposing

Johnson & Johnson (NYSE: JNJ) is advancing its gene therapy candidate Botaretigene sparoparvovec for X-linked retinitis pigmentosa in ongoing regulatory and clinical processes.

The pharmaceutical group has expanded work on drug repurposing programs that apply AI tools to reanalyze existing compounds for oncology and rare diseases.

Management has taken a leading role in global collaborations focused on AI-driven compound repurposing, adding to its rare disease research footprint.

This push into gene therapy and AI-led drug repurposing aligns with the wider trend towards specialized treatments in healthcare.